Erschienen in:
01.09.2006 | Original Paper
Clinical Response Is Associated with Elevated Plasma Interleukin-1 Receptor Antagonist During Selective Granulocyte and Monocyte Apheresis in Patients with Ulcerative Colitis
verfasst von:
Kyoya Sakimura, Toshihide Omori, Etsuro Iwashita, Takeshi Yoshida, Yoshikazu Tsuzuki, Kenji Fujimori, Fumio Konishi, Yukio Yoshida, Hiroo Anzai, Hiromichi Suzuki, Souichi Sugawara, Yuji Takeda, Katsuya Hiraishi, Abbi R. Saniabadi, Tatsuo Ide, Soichiro Miura, Shinichi Ota
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 9/2006
Einloggen, um Zugang zu erhalten
Abstract
Depletion of granulocytes and monocytes (GM) by selective apheresis (GMA) with an Adacolumn exerts an anti-inflammatory effect in patients with ulcerative colitis (UC) or rheumatoid arthritis. However, the mechanism of the anti-inflammatory effect of GMA is not fully understood yet. We investigated the effect of GMA on the plasma concentration of interleukin-1 receptor antagonist (IL-1ra), a potent anti-inflammatory cytokine. Twenty-six patients with active UC received GMA at one session per week for 5 consecutive weeks. Clinical response was defined as Δclinical activity index (ΔCAI=CAI at entry – CAI at post)≥4, while clinical remission was defined as CAI≤4. Twenty-one of twenty-six patients (80.8%) responded to GMA. In the first session, plasma from responder patients showed a significant (P < 0.01) increase in IL-1ra in the Adacolumn outflow. In contrast, there was no change in IL-1ra in nonresponders. In conclusion, release of IL-1ra during GMA might be one mechanism of clinical efficacy associated with this therapy.